InvestorsHub Logo
Followers 78
Posts 3789
Boards Moderated 0
Alias Born 12/21/2008

Re: None

Monday, 04/09/2012 1:11:35 AM

Monday, April 09, 2012 1:11:35 AM

Post# of 77519
While this is an old link it connects ...

Looking specifically at the follicular lymphoma patients, 85% (38/44) evaluable FL patients achieved a complete response.

http://www.news-medical.net/news/20110618/Celgene-announces-data-from-REVLIMID-plus-rituximab-Phase-II-study-on-malignant-lymphomas.aspx

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.